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ABSTRACT 
The general aim of this thesis was to contribute to a better understanding of the development 
and progression of leukemia in children. Biological markers identified in children with 
leukemia can contribute to the understanding of leukemic development.   
Several studies have traced biological markers associated with leukemia back to a prenatal 
origin by analyzing neonatal blood spots (NBSs) indicating that these markers are early 
events in leukemogenesis. The fusion gene STIL-TAL1 occurs with a frequency of 11-27% at 
diagnosis of T-cell acute lymphoblastic leukemia (ALL) in children. The developmental 
timing of this fusion gene is unknown yet, STIL-TAL1 is exclusively found in T-cell ALL 
hence could be a key event in development of this type of leukemia. 
Response to antileukemic treatment is important for prognosis in leukemia, but also specific 
molecular cytogenetic markers are important for classification and risk assessment. Mutations 
in the tumor suppressor gene TP53 are the most common genetic aberrations in cancer and 
analysis of altered expression of its protein product p53 has shown to have potential as a 
predicitve marker for adverse outcome in leukemic patients. 
In scientific paper I, we investigated if the fusion gene STIL-TAL1 is present early in life by 
analyzing NBSs from 38 patients who developed T-cell ALL in childhood. DNA was 
extracted from the NBSs and analyzed for the fusion gene STIL-TAL1 by nested polymerase 
chain reaction and electrophoresis. We could not detect the presence of STIL-TAL1 in any of 
the 38 neonatal blood spots from pediatric T-cell ALL patients, indicating that STIL-TAL1 
most probably is a post-natal event in development of T-cell ALL in children 
In scientific paper II, III and IV we investigated if alterations in expression of specific cell 
cycle regulating proteins can predict relapse after hematopoietic stem cell transplantation 
(HSCT). Protein expression of p53 were analyzed in 33 patients with rare myeloid 
malignancies, 34 patients with acute myeloid leukemia (AML) and in 46 patients with B-cell 
ALL respectively. Protein expression was analyzed by immunohistochemistry (IHC) on 
tissue micro arrays. In study II, increased expression at diagnosis significantly predicted 
relapse after HSCT in children with rare myeloid malignancies.  In study III, we found a 
higher p53 expression at three to six months after HSCT in the AML patients that relapsed 
compared to the group of patients who did not relapse. In study IV we found that an intense 
expression of p53 protein within three months after HSCT predicted relapse in patients with 
ALL. In summary, we conclude that aberrant protein expression of p53, analyzed by IHC 
which is a well-established method available at most hematological laboratories, may have 
potential as a prognostic marker to predict relapse after HSCT in pediatric leukemia.  
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1 INTRODUCTION 
1.1 LEUKEMIA  
Cancer- an abnormal growth of cells which tend to proliferate in an uncontrolled way - is the 
name we use for over two hundred different diseases that differs in their tissue of origin and 
genetic composition. This thesis concerns pediatric leukemia, a cancer that arise from blood 
cells and that is the most common malignancy in children. 
1.1.1 Short history of leukemia 
In 1844 a French physician named Alfred Donné observed several patients with increased 
amount of white blood cells (WBCs). He suggested that it would be due to developmental 
arrest of the WBCs. One year later in 1845, the British professor John Hughes Bennet 
described the abnormalities he observed in the blood during an autopsy of a 28-year-old man, 
in a post mortem report. He called it “leukocythemia” and suggested that was due to a 
systemic hematopoietic disorder rather than caused by inflammation. After similar 
observations in an autopsy of a 50-year-old women later the same year, the German 
pathologist Rudolf Virchow published a paper with the title “Weisses Blut” meaning “White 
Blood”. A few years later he named the disease “Leukämie” after the Greek words leukos 
meaning clear or white, and haima meaning blood 1. 
In 1850, the first report of leukemia in a pediatric patient was published by Henry William 
Fuller who described a 9-year-old girl who had been admitted at St Georges Hospital in 
London with symptoms such as frequent bleedings, high white cell count in blood and an 
enlarged spleen. Fullers detailed description of the case has later allowed experts to believe 
that this was a case of chronic myeloid leukemia (CML) 2. The girl died from her disease 
after just a few months and pediatric leukemia continued to be a fatal disease for many years.  
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One century later, in 1948 the use of chemotherapeutic substances showed to induce 
temporary remission in leukemic patients.  In 1961, after treating 39 leukemic pediatric 
patients with a combination of two chemotherapeutic agents, Frei et al reported complete 
remission in 59%, and a 2-year survival rate in 20% of patients in the same group 3. A year 
later at St. Jude Children’s Research Hospital a new approach to cure leukemia was induced 
including multiple therapies, central nervous system (CNS) -directed therapy with cranial 
radiation, therapies including remission induction, consolidation therapy and continuation 
treatment 3. This laid the foundation for modern therapy where multiple target therapy is still 
the backbone for treatment of leukemia.  
Another milestone in leukemia treatment was in 1957 when E. Donnall Thomas published a 
paper in New England Journal of Medicine where he had treated six patients with infusion of 
bone marrow (BM) cells from an unrelated donor. Despite engraftment in two patients, all six 
patients died within 100 days 4. Nevertheless the potential of the treatment was not forsaken, 
and since then the knowledge concerning patient specific human leukocyte antigens (HLA) 
has increased. Today, the patients can receive a hematopoietic stem cell transplantation 
(HSCT) from an HLA compatible sibling donor, as well as a matched unrelated donor. The 
donor graft is supposed to replace the patient graft and thereby induce a graft versus leukemia 
(GVL) effect. Other factors that contribute to a better overall survival after transplantation are 
e.g early detection and treatment of virus infections and good nutritional care. Today 
allogeneic stem cell transplantation is a lifesaving treatment for many leukemia patients.  
Due to better knowledge concerning the biology and the genetics of the disease the treatment 
of leukemia has improved, with e.g optimized dosage of chemotherapy, more target directed 
drugs, early detection of infections and better supportive care. The 5-year survival rate for 
pediatric leukemia has increased from 10% in the 1960s to almost 80% in the 1990s 5. Since 
then survival rates have continued to slowly rise and are now 90% for pediatric acute 
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lymphoblastic leukemia (ALL) cases and close to 70% for pediatric acute myeloid leukemia 
(AML) cases in several western countries 6,7.  
Yet, there are still children who cannot be cured from their disease and hopefully more 
research will continue to improve the prognosis for all children diagnosed with leukemia.   
1.1.2 Pediatric leukemias 
Approximately 70 children are  diagnosed with leukemia each year in Sweden 8. Leukemia 
can be separated into several different subtypes, depending on their origin of the stem cell 
linage in the bone marrow; lymphoid or myeloid origin. 
1.1.2.1 Acute lymphoblastic leukemias 
ALL affects the lymphoid cells and accounts for approximately 80% of all pediatric leukemia 
cases. ALL can affect both B and T- cell linages and results in an increased amount of 
immature and non-functional lymphoblasts. For B-cell ALL there is an incidence peek 
between 2-5 years 9. T-cell ALL is a rare form of pediatric ALL, accounting for about 15% of 
acute lymphatic leukemias. T-cell ALL is more prevalent in older children with a boy to girl 
ratio of 3:1. Long term survival rates in children with ALL have reached 90% in certain 
developed countries and for T-cell ALL they are 70-90% 6,10,11. 
1.1.2.2 Myeloid leukemias 
The myeloid leukemias are further divided into different subtypes. AML accounts for 
approximately 15% of all childhood leukemia cases. In turn, AML patients can be even 
further divided into different risk groups considering morphology, karyotype and molecular 
alterations, according to the World Health Organization (WHO) classification system. For 
children with AML survival rates are approaching 70% 7,12.  
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Approximately 5% of pediatric leukemias consist of the rare myeloid malignancies 
myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML) and CML 
8,12.  
MDS is a rare disease in children defined by clonal defects causing unsuccessful 
hematopoiesis and symptoms such as neutropenia and thrombocytopenia and predisposition 
to develop AML. Approximately 50% of children with MDS are cured by HSCT 13.  
JMML is an aggressive proliferative disorder characterized by excessive proliferation of 
monocytic and granulocytic cells, mostly affecting young children and the event free survival 
after HSCT is around 50% 13,14.   
CML mostly affects older children >10 years, often presented with splenomegaly and high 
WBC counts. CML is characterized by presence of the fusion gene BCR-ABL, also called the 
Philadelphia chromosome 15. There are three clinical phases of CML; chronic, accelerated 
and blast crisis, and treatment success correlates to what phase the patient is diagnosed in. 
Most patients are diagnosed in chronic phase and long term survival rates are between 60-
80% 16.  
1.1.3 Treatment   
Improvement in treatment such as better risk classification, improved therapies, better 
supportive care and discovery of clinical usable tools to monitor disease progression has 
resulted in significant enhanced survival in children with leukemia. Pediatric leukemias are 
treated according to different regional protocols often based on biological, clinical and 
genetic features such as lymphoid or myeloid origin, age of the patient, WBC levels, CNS 
status and genetic markers. In Sweden pediatric leukemia patients are treated according to 
protocols from the Nordic Society for Pediatric Hematology and Oncology (NOPHO). 
Response to therapy, measured through minimal residual disease (MRD) analysis, has 
emerged as an important factor for risk stratification during treatment. Choice of therapy is 
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based on current knowledge in the field, for example when tyrosine kinase inhibitors (TKIs) 
showed to induce remission in leukemia patients positive for the Philadelphia chromosome, 
the majority of this group of patients was no longer directly considered candidates for HSCT 
17. Yet, for AML patients, classified as high risk and in complete remission (CR) 1 or those 
with poor response to initial treatment, HSCT has shown to be a preferable therapy to cure 
disease 18,19. In recent years genetically engineered T-cells expressing a chimeric antigen 
receptor (CAR) has shown great potential in treatment of pediatric ALL patients who 
relapsed or responded poorly to conventional therapy 20. 
1.1.3.1 Relapse 
Relapse is one of the major obstacles in treatment of leukemia. Studies have shown that the 
leukemic clone seen at relapse may differ from the clone identified at diagnosis. Sometimes 
the relapsed clone may have been present as a minor subclone when the leukemia first was 
diagnosed, in other cases the relapsed clone is identical to, or even very different from the 
original clone. The relapsed clone tend to be more resistant to chemotherapy which in one 
reason why patients who relapse have poor prognosis 17 
1.1.3.2 Hematopoietic stem cell transplantation   
Although the general survival has improved remarkably in the last decades there is still a 
small portion of children with more aggressive malignancies that are candidates for HSCT 
such as patients with JMML and MDS 14. Furthermore, ALL and AML patients diagnosed 
with specific cytogenetic or molecular markers indicating unfavorable prognosis, some 
children that relapse as well as children with poor response to chemotherapy, are also 
candidates for HSCT. For example, after induction chemotherapy 90% of children with ALL 
and AML achieve CR, but 10-15% of ALL cases and 30–40% of AML cases still relapse 
12,21–24. Patients that are detected with an intermediate response after first induction therapy, 
yet receive morphological remission after the second induction still have a high risk of 
relapse 24. The over-all survival for ALL patients who relapse is poor, about 50% 25.  In this 
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group of patients, there is still a need for new clinical and biological markers that can indicate 
prognosis and thereby aid in the decision of what therapy to give 21,26.  
Even though HSCT offers  an effective and life-saving treatment, 20-60% of children still 
relapse after HSCT making it the major course of treatment failure in children that undergo 
HSCT due to malignant disease 27–30. New prognostic markers indicating a forthcoming 
relapse after HSCT would be a major contributor to more individualized therapy for the 
vulnerable group of children with more aggressive leukemia. 
1.1.3.3 Prognostic tools after HSCT 
There are two major tools for monitoring success of treatment after HSCT; analysis of MRD 
and chimerism. In brief, MRD analysis measures the leukemic clone directly whereas 
chimerism analysis measurers the ratio of donor/recipient graft in the bone marrow 26. An 
ideal MRD marker should be present in all leukemic cells and absent from all non-leukemic 
cells. A detected MRD or elevated recipient cells in the chimerism analysis demonstrate the 
need for therapeutic interventions such as lowering of immunosuppression or donor 
lymphocyte infusion (DLI). These interventions which will boost the GVL effect however, 
might induce graft versus host disease (GVHD) which is another severe and potential life-
threatening condition, hence there is a delicate balance to consider when deciding what 
therapy to give these patients 31. DLI was first shown to be effective in CML-patients after 
HSCT by Kolb et al. Administration of DLI has shown to induce CR in 8% of ALL-patients 
and 22% of AML-patients. However, if chemotherapy is used to reduce tumor burden before 
DLI CR is further improved to 33% and 37% in ALL and AML patients respectively 32.  DLI 
has also shown to be effective when given if mixed chimerism is detected without signs of 
MRD 31. Therefore chimerism test and MRD is recommended as a regular schedule in the 
post-transplant period to improve the possibility of detecting a forthcoming relapse early 32,33. 
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1.1.3.4 Minimal residual disease  
MRD is currently the most effective tool to monitor effectiveness of treatment in ALL and 
has also emerged as a reliable tool in AML 6,9. MRD are used for risk stratification and can 
help to identify those patients who may benefit from a HSCT. Also, MRD levels before 
HSCT are strongly associated with outcome after HSCT 29,30,32.  
Two different approaches are used to detect MRD, clone-specific quantitative polymerase 
chain reaction (PCR) and multiparameter flow cytometry (MPFC) detecting abnormal 
immunophenotypes, both reaching a sensitivity of 10-4 cells 34. PCR is used to clone 
breakpoints of common leukemic fusion genes and genetic mutations previously identified in 
the leukemic cells. The usefulness of these aberrations as targets for MRD depends on their 
stability during the course of the disease. MPFC detects leukemia associated phenotypes 
(LAPs) as leukemic cells often present hematopoietic antigens, such as T-cell receptors and 
immune globulin gene rearrangements, in combinations that are unusual in healthy cells thus 
provide a possibility to monitor survival of the malignant cells after treatment 35. A detected 
MRD of ≥0.01% leukemic cells at day 29 after induction therapy indicates the need for 
intensified treatment in patients with ALL. MRD is also used for risk assessment in AML 
patients where the generally accepted lower limit for detection is 0.1% of leukemic cells, and 
high MRD, despite morphological remission might indicate HSCT 24,36.  
1.1.3.5 Chimerism 
Chimerism, analyzed by PCR using short tandem repeats to identify donor and host graft, 
monitors the possible event of re-appearance of recipient cells after HSCT. Patients with 
rapid increased mixed chimerism after HSCT may be at risk of relapse 26,33.  
1.1.4 Etiology 
The etiology of most pediatric leukemias are unknown. Less than 5% of cases are believed to 
be due to germ-line genetic aberrations resulting in syndromes such as Down syndrome or 
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Bloom syndrome, or to ionizing radiation or exposure to chemotherapeutic drugs 37. Many 
studies throughout the years have investigated different possible risk factors such as parental 
or early childhood exposure to non-ionizing electromagnetic fields, pollution, and maternal 
smoking during pregnancy however, none of these have been clearly implicated 38. Old 
parental age has been associated with increased risk of developing childhood leukemia in the 
offspring in some studies 39,40. Also, vaccination and virus-studies has been performed 
without conclusive results 38,41. Children born with Li-Fraumeni syndrome, caused by 
inherited mutations in the TP53 gene, have an increased risk of developing leukemia. Being a 
twin does not mean an overall increased risk of developing leukemia but if one of the twins 
develop disease during early childhood an increased risk has been observed for the second 
twin, which might indicate a possible pre-natal genetic involvement 38.  
Two major hypothesis, both suggesting that infections promote pediatric leukemia, has been 
proposed in the literature; Kinlens “population mixing” theory and Greaves “delayed 
infection” theory. Kinlen suggested that the immigration of people to previously remote areas 
exposing the original inhabitant’s immune defenses to previously un-encountered infectious 
agents could trigger the development of leukemia. Greaves proposed that leukemia 
development is generated by genetic aberrations occurring in a two-step matter where the first 
step is prenatal and the second step is post-natal and may be triggered by an infection 38,41. 
The role of infections in ALL is still controversial 42. However, there is a growing body of 
evidence indicating that the initial event is a genetic aberration occurring prenatally in 
children that later develop leukemia, as discussed further in section 1.3.  
1.2 MOLECULAR MARKERS IN PEDIATRIC LEUKEMIAS 
1.2.1 Acute lymphoblastic leukemia 
Molecular markers have had a great implication in treatment of B-cell ALL, both in risk 
stratification and as targets for MRD analysis. Examples of cytogenetic markers commonly 
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used for risk stratification in ALL are ETV6-RUNX1 (t(12;21)) and high hyperdiploidy (> 50 
chromosomes) which occurs in about 25% of childhood ALLs respectively. These markers 
are associated with good prognosis and the overall survival for patients with ETV6-RUNX1 
positive ALL or a high hyperdiploid karyotype are over 93%. Markers indicating poor 
prognosis hence indications for HSCT are the fusion gene BCR-ABL (t(9;22)), translocations 
involving the MLL gene with different partner genes and, hypodiploidy (< 44 chromosomes) 
which are found in approximately 3%, 5% and 1% of cases respectively 17,43,44.  
Frequency of translocations varies with age as ETV6-RUNX1 and BCR-ABL are more 
common in older children whereas translocations involving the MLL gene are present in 80% 
of patients less than 1 year 9. Among this subgroup of infant MLL-positive patients the 5-year 
survival is 50% 17.  
Intrachromosomal amplification of chromosome 21 (iAMP21) is due to instability of 
chromosome 21 and occurs in about 2% of ALL patients, mostly in older children. It was 
previously associated with poor prognosis but can now be treated with intense chemotherapy 
17.  Other chromosomal abnormalities such as dic(9;20) and t(1;19) occurs in approximately 
2% and 3% of pediatric ALLs respectively, and children with these aberrations are classified 
as intermediate risk in the NOPHO protocol for treatment of pediatric ALL 45.   
Deletions the IKZF1 gene have been associated with poor prognosis, and are found in 
approximately 15-16% of B-cell ALLs 44,46–48. It is often seen in patients with Philadelphia-
positive ALL and associated with poor outcome despite TKI therapy suggesting that these 
patients could benefit from more intense treatment 46. Germline variations of IKZF1 have 
been found in both familial childhood ALL and sporadic ALL indicating that alterations in 
this gene may have a predisposing significance in pediatric ALL 49.  
TCF3-HLF (t(17;19)) is another fusion gene that has been associated with very poor 
outcome. TCF3-HLF is rare and have mostly been identified in older children 50. 
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Deletions of the CDKN2A gene, encoding the protein p16, has been reported in 25-36% of 
pediatric B-cell ALL cases and associated with high WBC count and poor prognosis 44,46,51.  
Although TP53 mutations are rare at diagnosis of pediatric ALL, they are more common in 
certain subgroups such as hypodiploidy ALL or ALL with N-MYC rearrangements 52,53.  
Mutations of TP53 are associated with lower overall survival (OS), lower event free survival 
(EFS) and higher relapse rate (RR) 54. Alterations in TP53 in pediatric leukemia is discussed 
more in section 1.4 
1.2.2 T-cell acute lymphoblastic leukemia 
In contrast to B-ALL, and although chromosomal translocations are present in 50% of T-cell 
ALL their prognostic indications are not well identified and therefore not routinely used for 
risk stratification. TLX3 rearrangements have been found in more than 20% of patients but the 
prognostic significance is not established 55,56. The fusion gene STIL-TAL1 is present in 11-
27% of children with T-cell ALL at diagnosis 55,57–62. STIL-TAL1 is exclusively found in T-
cell ALL and can be used as a tool to monitor MRD during treatment therapy 63, however, the 
prognostic value of this genetic aberration is not established although preliminary data show a 
favorable prognosis  55,56,59,60,62. It has been suggested that this fusion gene could be an early 
or initiating event in T-cell ALL 64.  Despite these observations the fusion appears to be very 
rare at diagnosis in infant T-cell ALL patients 65, but its presence increases with age, peaking 
at 10-15 years 55,58. Yet, STIL-TAL1 it is still more common in children and adolescents than 
in adults 66  
NOTCH1 mutations are seen in more than 50% of T-cell ALL and may indicate a good 
prognosis 17,67. Deletions in the CDKN2A gene are found in 60-80% of pediatric T-cell ALL 
patients 68. Mutations in the tumor suppressor gene PTEN was found in 12% of 257 pediatric 
T-cell ALLs in a study that indicated that PTEN mutations could have inferior prognosis 67.  
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1.2.3 Acute myeloid leukemia 
AML is a very heterogeneous disease with a great range of genetic aberrations yet the use of 
risk markers has not been as extensively used as in ALLs. However, molecular markers 
commonly seen in AML include RUNX1-RUNX1T1 (t(8;21)), inv(16) and MLL 
rearrangements and mutations in FLT3, NRAS, PTPN11 12. Mutations in NPM1 and 
overexpression of WT1 are also found in AML patients and are target candidates for MRD 
analysis 36,69. FLT3 , which is an indication for HSCT, and WT1 are associated with poor 
outcome whereas NPM1 and the MLL rearrangement t(1;11) is associated with a favorable 
outcome in AML patients 12.  
1.2.4 Myelodysplastic syndrome 
Monosomy 7 is the most frequent molecular marker in MDS. Germline mutations in GATA2 
and RUNX1 are associated with predisposition to MDS 70. Also, mutations in genes involved 
in the Ras-MAPK pathway such as PTPN11 and NRAS are common in pediatric MDS 
patients 71.  
1.2.5 Juvenile myelomonocytic leukemia 
Monosomy 7 is also found in 25% of JMML cases. Somatic mutations in KRAS, NRAS and 
PTPN11 are present in 50% of JMML patients 14. PTPN11 also occur as germline mutation in 
JMML patients with Noonan syndrome 13. Several of the genetic alterations found in JMML 
patients are involved in the RAS signaling pathway yet they are associated with different 
prognostic outcomes as NRAS indicates good prognosis and PTPN11 seems to have an 
unfavorable outcome 13,14.  
1.2.6 Chronic myeloid leukemia 
Chronic myeloid leukemia is characterized by the BCR-ABL fusion gene 72. The fusion 
induces a constantly activated tyrosine kinase which results in increased cell proliferation. 
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The altered tyrosine kinase activity can be inhibited by TKIs, which can result in long term 
remission in most patients 16.  
1.3 EVIDENCE FOR PRENATAL ORIGIN OF PEDIATRIC LEUKEMIA 
Chromosome translocations could be the first events in leukemogenesis, occurring in utero in 
some cases of pediatric leukemia 73. These genetic changes are considered to be necessary, 
but not sufficient to cause overt leukemia. Studies of NBSs confirm that some leukemias may 
have their origin in utero, when myeloid and lymphoid cells are not fully differentiated and 
are therefore more sensitive for malignant transformation 73. Several important factors 
affecting the potential prenatal phase of ALL are unknown, such as time of initiation and 
causes of initiating events 74. Hence genetic alterations could originate at time of conception 
or later during hematopoiesis in utero. 
Foetal haematopoiesis begins in the haematogeneic endothelium from the yolk sac, then 
mainly continues in the liver and is finally established in the bone marrow and spleen 75. The 
yolk sac is the major site of embryonic erythropoiesis with the primary purpose to produce 
red blood cells that can facilitate tissue oxygenation as the embryo undergoes rapid growth.   
These erythroid progenitor cells are not pluripotent and do not have renewal capability. Stem   
cell development occurs later and give rise to all blood lineages. These migrate to the fetal 
liver and then to the bone marrow, which is the final location for hematopoietic stem cells 76. 
The B-lymphocytes arise in the liver at 8 weeks of gestation but can be detected in the blood 
circulation at gestational age of 12 weeks. T-cells progenitors, also derived from the liver 
from seven weeks of gestation, migrate to the thymus by 8 - 9 weeks of gestation and 
circulating mature T-lymphocytes are first detected around gestational week 15 to 16 77.  
Through studies of NBSs and monozygotic twins some childhood ALLs can be traced back 
to a prenatal origin, starting in utero with a preleukemic clone, followed by the acquisition of 
postnatal genomic losses or gains subsequent to the prenatal primary cytogenetic aberration 
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65,78–84. Genetic aberrations that have been traced back to a prenatal origin are MLL-AF4, 
ETV6-RUNX1, ETV6-ABL1 and BCR-ABL fusions 78,82,85–87. 
Ford et al, were first to identify the same unique fusion sequence for ETV6-RUNX1 in a pair 
of monozygotic twins who developed leukemia at the ages of three and four years 
respectively. The authors suggested that this genetic aberration was not sufficient for 
leukemia development, hence secondary alterations are required for disease to occur 88. This 
was further supported in a study by Ma et al, where identical breakpoints for the fusion gene 
ETV6-RUNX1 were identified in a pair of monozygotic twins in bone marrow sampled at the 
time of diagnosis of ALL, also indicating a in utero origin for the translocation  81. They also 
found secondary genetic alterations that were not identical between the twins and that likely 
occurred after birth. This indicates that ETV6-RUNX1 may be an early event in leukemia 
development however, secondary events are necessary for ALL to arise 81,89. Further support 
for the need of secondary post-natal mutations are found in a study where the ETV6-RUNX1 
fusion RNA was detected in cord blood in 1% of 567 healthy individuals, which is a higher 
prevalence than the occurrence of ALL in children 90. These results were also supported by 
Zuna et al, who detected the ETV6-RUNX1 fusion in 2% of NBS from 256 healthy newborns 
91. However, a larger study found no evidence of ETV6-RUNX1 transcripts in cord blood 
from 1417 healthy individuals, and another study could not detect the ETV6-RUNX1 
transcript in RNA extracted from NBSs from fifteen children who later developed leukemia 
or in thirty controls 92,93. Nevertheless, in a most recent study the ETV6-RUNX1 was detected 
in 5% of newborns and the authors suggest that the controversy regarding the prevalence of 
this fusion gene in healthy newborns may be due to differences in the methods used 94. Taken 
together these findings suggest that the genetic event giving raise to the ETV6-RUNX1 fusion 
gene is a primary event that occurs in utero, however it has a very low potential of inducing 
leukemia. 
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In a study by Cazzaniga et al, BCR-ABL1 fusion genes were detected in two twin pairs. One 
pair, both diagnosed with ALL shared the genomic sequence for the fusion gene, and it was 
also traced back to their NBSs, indicating that it was a pre-natal event. The other pair both 
expressed BCR-ABL1 positivity in their NBSs however, only one twin developed leukemia. 
This second finding also demonstrates that secondary post-natal mutations are needed to 
develop disease 82. 
Evidence for an in utero origin for MLL rearrangements and a hyperdiploid karyotype in 
pediatric leukemia has also been proposed in the literature, indicating that also these 
aberrations may be of importance as first events in leukemogenesis 78,95–97. Also, ETV6-ABL1 
has been traced back to the NBS from a boy that developed B-cell ALL at the age of two 87. 
Recognition of a strong association between preleukeimc fusion genes and development of 
disease could also encourage screening of donor source prior to HSCT. Donor cell leukemia 
(DCL) have been reported to represent 5% of leukemic relapses after HSCT 98. Although 
DCL is very rare, it is a severe event with poor outcome 99,100. It has been suggested that DCL 
occurrence is similar amongst the different sources of donor cells, such as bone marrow, 
peripheral blood stem cells and cord blood. 101.  
1.4 TP53 AND PEDIATRIC LEUKEMIA 
TP53 is a tumor suppressor gene located at the short arm of chromosome 17. The TP53 gene 
encodes the p53 transcription factor protein p53, which has a key role in regulating the cell 
cycle by preventing damaged DNA to be replicated. Normally p53 protein levels are very low 
in a cell. p53 is regulated by another protein MDM2, which ubiquiylates p53 and thereby 
targets it for degradation. However, in responds to several stress factors such as DNA 
damage, hypoxia and oncogene activation p53 gets phosphorylated and is no longer 
recognized by MDM2 and levels of p53 rises in the cell. p53 acts by initiating transcription of 
genes such as p21 which in turn inhibits Cdk2 and thereby causes cell cycle arrest, and 
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PUMA and BAX that by activating different signaling pathways initiate apoptosis. Because 
of its important role in preventing damaged DNA to replicate, p53 is often called the 
“guardian of the genome” 102. TP53 alterations are reported with a frequency of 10-40% in 
different adult hematological malignancies, mainly seen in disease with a progressive course 
103,104. The knowledge regarding prevalence and impact of TP53 alterations in pediatric 
hematological malignancies is also increasing.  
In pediatric ALL, alterations of TP53 appear to be rare at diagnosis yet more common in 
relapsed cases. TP53 mutations have been found in 2-3% of children at diagnosis of ALL, but 
in 10-12% after relapse, indicating involvement in progression to more aggressive disease 
43,54,105–109. Yet, one study found TP53 mutations in 14.5% of sixty-two children with ALL 
and the patients with TP53 mutations also had a high expression of p53 however, these 
results were not associated with outcome 110. Gustafsson et al, have previously reported an 
increased expression of p53 protein in bone marrow samples from a group of children eligible 
for HSCT diagnosed with ALL, AML, MDS and CML, compared to a group of patients with 
non-malignant bone marrow disorders 111 
For the myeloid malignancies the data is less conclusive. One study found TP53 mutations in 
1.1% of 206 pediatric AML patients and, the patients with TP53 mutations had poor 
outcomes 112. Immunohistochemical analysis of a mutant form of p53 expression was 
suggested as a possible method for detecting MRD in a case report of a pediatric patient with 
AML 113.  In another study, no TP53 mutations were detected in twenty-seven patients with 
AML or in two patients with CML 106. In a study analyzing TP53 mutations in twenty JMML 
patients, and also p53 expression in eight of these patients, results were negative 114. Saito et 
al, also analyzed TP53 mutations in eighteen patients with JMML with negative results. 
However, in the same study they found a TP53 mutation in one out of nine patients with 
MDS and this patient also had an overexpression of p53 in 20% of BM cells and a poor 
outcome 115.  Silveira et al, found loss of TP53 in 95% of patients in a study group consisting 
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of nineteen children with MDS, suggesting that this alteration may be involved in 
development of pediatric MDS, whereas Schwartz et al, only found TP53 mutations in 4% of 
seventy-seven children with MDS 71,116.  Contrary, in a study investigating the mutational 
differences in adult and pediatric MDS, no mutations in the TP53 gene were detected in 50 
patients below 18 years of age, and the authors suggested that this mutation is not involved in 
pathogenesis of pediatric MDS, which were in agreement with the results and conclusion 
from yet another study where no TP53 mutations were found in 35 children with MDS 70,117.  
1.5 P16, P21 AND PTEN 
Mutations in the CDKN2A gene, encoding protein p16, are common genetic alterations in 
cancer and are found in approximately 30% of pediatric ALL cases and in 60-80% of T-cell 
ALL cases 44,51,68. In the cell cycle p16 inhibits the cyclin-dependent kinase 4/Cyclin D 
complex therefore induce phosphorylation of the retinoblastoma protein RB1 and promote 
cell cycle progression.  
p21 protein, the product of the CDKN1A gene, is regulated downstream of the p53 protein 
and activation of this protein induces cell cycle arrest 118. Alterations in the p21 pathway has 
been correlated to leukemogenesis in AML1-ETO positive AML 119. In adult patients with 
MDS, low levels of p21 has been associated with progression to AML and lower overall 
survival rates 120.  
PTEN (phosphatase and tensin homolog) is a tumor suppressor gene and one of the most 
altered genes in cancer with mutations seen in 30-80% of different cancers such as 
endometrial carcinoma, glioblastoma, prostate, breast, colon and lung cancer. Germline 
mutation in this gene causes Cowden Disease and predisposition to several cancers 121. 
Deletions of PTEN has also been found in approximately 10% of pediatric T-cell ALL 67,122.  
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2 AIMS OF THE THESIS 
The general aim of this thesis was to increase our understanding regarding the origin and 
development of pediatric leukemia. This was done by investigating if a specific leukemia 
associated genetic aberration can be traced back to a prenatal origin (study I) and, by 
evaluating if protein expressions differs between leukemic patients during treatment, hence 
can be predictive for relapse after hematopoietic stem cell transplantation in children with 
leukemia (study II-IV). Specific aims were; 
Study I 
Is the fusion gene STIL-TAL1 present in DNA from neonatal blood spots from thirty-eight 
pediatric patients with T-cell ALL? 
Study II 
Can aberrant expression of the cell cycle regulating protein p53, analyzed by 
immunohistochemistry (IHC), act as a predictive marker for relapse after HSCT in children 
with MDS, JMML and CML? Is altered p53 expression due to underlying mutations in the 
TP53 gene? 
Study III 
Does altered expressions of the cell cycle regulating proteins, p53, p21, p16 and PTEN, 
analyzed by immunohistochemistry, have potential as predictive markers for relapse after 
HSCT in children with AML? 
Study IV  
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Can expression of the cell cycle regulating protein, p53, analyzed by 
immunohistochemistry, act as a predictive marker for relapse after HSCT in children with 
ALL? 
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3 MATERIAL AND METHODS 
3.1 STUDY I 
3.1.1  Neonatal blood spots 
In Sweden, blood spots from newborns have been taken within 48 hours after birth since 
the mid-60s, with the main purpose to analyze for twenty-four rare but often treatable 
diseases, such as endocrine and metabolic disorders. The NBSs are collected onto filter 
paper called Guthrie Cards. Since 1975, Guthrie cards have been saved and stored for the 
main purpose to be used in quality controls of screening program itself and for potential 
future use in medical care. However, this unique material can also be used for research after 
ethical approval.  
Previously, Guthrie cards from 417 Swedish children who developed childhood B-cell or T-
cell ALL in 1992-2006, together with 834 controls matched by birth date and birth place, 
have been collected. From each Guthrie card four small spots (3 mm in diameter) were 
punched out, estimated to contain approximately 12 µl of blood corresponding 
approximately 180,000 leukocytes and 120,000 lymphocytes. The median storage time for 
the NBSs was 9.9 years (range 2.6 - 22.8). DNA extraction was carried out by the minimal 
essential medium (MEM) method, based on a method described by Barbi et al, 1996 and 
modified according to Priftakis et al, 2003 123,124. The DNA yield was ascertained by 
analyzing the samples for the human albumin gene by TaqMan real-time PCR. The DNA 
obtained has previously been used in several studies, where the primary aim was to find out 
if particular viruses could be involved in leukemia development, but no association between 
in utero infection by herpes virus, adenovirus or polyomavirus and development leukemia 
could be established 125–127.  
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For this thesis, I had the opportunity to use some of the frozen NBS DNA to investigate if 
the fusion gene STIL-TAL1, common at diagnosis of T-cell ALL, could be traced back to 
early stages of life in thirty-eight children who developed T-cell ALL between the ages of 1 
and 17 years.  
3.1.2 STIL-TAL1 fusion gene 
The TAL1 (T-cell acute leukemia) gene, located at 1p23, consists of eight exons, while the 
STIL (SCL/TAL1 Interrupting Locus) gene located at 1p32 consists of eighteen exons. 
STIL-TAL1 gene fusion occurs after an approximately 90kb interstitial deletion on 
chromosome 1, which joins TAL1 to the STIL gene and results in inappropriate activation of 
the TAL1 protein through the STIL gene promoter. Several deletions resulting in STIL-
TAL1 gene fusion have been described yet two of them, type I and type II, appear to be 
most common and represent 95% of total STIL-TAL1 cases and occur in 10-19% and 1-3% 
of pediatric T-cell ALL patients respectively 57,58,62.  Type I and II deletions appear to be 
driven by aberrant RAG recombinase activity since the breakpoints usually cluster at 
heptamer-nonamer recombination signal sequences (RSS); hallmarks of V(D)J gene 
joining.  Both type I and II deletions use the same cryptic heptamer RSS at the 5’ break in 
the STIL gene but can use either one of two 3’ RSS (only 1.7kb apart) found in the 5’ 
region of TAL1.   
3.1.3 Analysis of STIL-TAL1  
To ensure material quantity, NBS DNA was whole genome amplified (WGA) using the 
standard protocol for REPLI-g Mini Kit from QIAGEN. The NRAS gene was used as an 
integrity control for presence of DNA in the WGA NBS material.  
STIL-TAL1 type I and II fusions were analyzed independently by nested PCR based on a 
protocol described by Breit et al 1993 57. STIL-TAL1 PCR was performed using the 
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Accuprime Supermix II kit from Invitrogen, Life Technologies. In the first PCR 2-4 µl 
(depending on the intensity of the integrity control in the gel electrophoresis) of amplified 
DNA was used with the original STIL and TAL1 I/II primers, cycling conditions 3 min at 
94°C 2 min at 60°C 3 min at 72°C for 40 cycles, 7 min 72°C then hold at 12°C. In the 
second PCR, 2-4 µl of first PCR product was used with secondary STIL and secondary 
TAL1 I/II primers for (for primer sequences, see Study I -supplementary data), cycling 
conditions 1 min 94°C then 30 sec 94°C, 30 sec 60°C, 30 sec 72°C for 35 cycles with a 
final 5 minute extension at 72°C. PCR was analyzed by electrophoresis in a 2.5% agarose 
gel stained with ethidium bromide. 
3.2 STUDY II-IV 
3.2.1 Material and study population 
Analysis of bone marrow is a standard procedure at diagnosis of leukemia and during 
treatment to monitor the patient’s response to therapy. To preserve the material for 
morphology and IHC analysis bone marrow samples are formalin-fixed, and paraffin 
embedded (FFPE) which also allows long time preservation hence this material can then be 
used for reevaluations and also research. 
We have collected FFPE BM samples from 133 children diagnosed with leukemia, who 
were treated with HSCT at Karolinska University Hospital 1997-2010. We collected 
material from diagnosis, time of HSCT and from routine controls at 3, 6, 12 and 24 months 
after HSCT. We also collected FFPE BM samples from 55 control patients, who had been 
investigated for bone marrow disorder but cleared from malignancy. In total, we collected 
438 bone marrow samples.  
The study group consisted of; forty-nine patients with B-cell ALL, seventeen patients with 
T-cell ALL, thirty-four patients with AML, nineteen patients with MDS, nine patients with 
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JMML and five children with CML. The control group consisted of 2 healthy bone marrow 
donors and 53 children with the following conditions; 4 children diagnosed with 
thalassemia, 13 children with aplastic anemia, 7 children with Fanconi aplastic anemia, 3 
children with amegakaryocytic thrombocytopenia, 1 child with Mb Hurler, 1 child with 
severe combined immunodeficiency, 4 children with Kostmann disease, 2 children with 
Wiscott Aldrich syndrome, 8 children with idiopathic thrombocytopenia, 1 child with 
chronic granulomatous disease, 1 child with hemolytic anemia, 5 children with suspected 
malignant disease, due to pancytopenia, but no malignant disease discovered, 1 child with 
neutropenia and 2 children with glycogenosis (Study II and III). In a later assessment we 
decided to exclude conditions which are considered to be pre-malignant, hence children 
with Fanconi aplastic anemia, Kostmann disease and Wiscott Aldrich syndrome were 
excluded, leaving forty-two children composing the control group in study IV.  
3.2.2 Tissue micro array, immunohistochemistry and Sanger sequencing 
Tissue micro array (TMA) is a cost effective and material saving technique. In TMA, only a 
small quantity of tissue is used from each BM sample and one microscope glass-slide can 
fit 120 samples. For our studies, TMA was prepared at the Center for Molecular Pathology 
at Malmö University Hospital.   
Two stances, one mm in diameter were punched out from each FFPE BM sample and 
placed in a paraffin block fitting 120 cores. The block was then cut on a microtome and the 
4mm thick slices were placed on object glass and deparaffinized. Each block produced 
several comparable microscope glass slides that could be stained for the proteins of interest.   
Immunohistochemistry was performed according to standardized protocols at the 
department of pathology, Karolinska University Hospital-Huddinge, using a Leica BOND-
III machine. Diaminobenzidine-peroxidase reaction weakly counterstained with 
hematoxylin visualized the antibodies. A positive control on a separate glass was included 
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in each set of staining.  Cells negative for the antibody in each sample served as negative 
controls.  
Expression of p53, p21, p16 and PTEN protein was analyzed in a microscope at high 
resolution (40X). p53 was analyzed as both total expression meaning all cells positive for 
p53, and strong expression meaning cells that had an intense expression of p53 identified as 
dark brown color in the nucleus after IHC. Analysis was blinded hence me and my 
colleague, who analyzed the TMAs, did not know if the sample belonged to a patient or 
control. For inclusion in our studies, a minimum of 100 cells were to be counted from each 
patient.  
For study II, Sanger sequencing was preformed according to standard protocols at the 
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm. M13-
tagged primers were used for mutation analysis of exon 2-11 in the TP53 gene. 
3.2.3 Statistical analysis 
All data was analyzed in Statsoft Statistica 11 (study II), 12 (study III) and 13.2 (study IV) 
and Excel 2011-2013.   
Logistic regression, which is a predictive analysis used when the dependent variable (in our 
case relapse) is binary (yes/no), was used to analyze the value of the protein expressions as 
predictive markers for relapse after HSCT.  
Box-plots were used in study II and III to visualize protein expression in the relapse group, 
the non-relapse group, and the controls at diagnosis. 
In study II, a time-to event curve (Kaplan-Meier analysis) was performed were the two 
groups of patients compared were based on median number of cells with positive p53 
expression at diagnosis (13.6%). A Log Rank test was preformed to analyze statistical 
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difference between the groups. Correlation between p53 and p21 expression was analyzed 
with a Spearman’s rank-order correlation test. 
Independent sample t-test were preformed to evaluate differences in p53 expression 
between the controls and the leukemic patients (study II and IV), and between the relapse 
group and the non-relapse group at all time points (study III).  
Results were considered significant if p < 0.05. 
  25 
4 RESULTS AND DISCUSSION 
4.1 STUDY I 
DNA from neonatal blood spots from thirty-eight children who developed T-cell ALL 
before the age of 18 were analyzed by nested PCR. STIL-TAL1 fusion type I or II were not 
detected in any of the thirty-eight NBS samples. The NRAS control gene was detected in all 
WGA NBS samples confirming the presence of enough DNA in the samples. The control 
samples were positive for STIL-TAL1 type I showing functional primers and PCR cycling 
conditions.  
Negative results of NBS analysis cannot be defined as true. Although it is possible that the 
investigated aberration does not have a prenatal origin, it may be that the leukemic clone, if 
present in the NBS, was missed when punching out the four pieces of the NBS that was 
used in this study or had not amplified sufficiently in the peripheral blood to be present in 
the spot. Our material contained approximately 120 000 lymphocytes per sample. Another 
limitation with our study was that we did not know if any of the patients included in this 
study had a STIL-TAL1 fusion gene at diagnosis. Yet, there are several reasons why our 
results could possibly represent true negative findings. 
Approximately 11-27% of children with T-cell ALL present with the genetic aberration 
STIL-TAL1 at diagnosis 55,57–62. We calculated that, according to what is reported in the 
literature 4-10 children of our thirty-eight included patients could be assumed to have this 
genetic alteration. Patients with STIL-TAL1 fusion often present with a high level of WBCs 
at time of diagnosis, and an higher prevalence of this fusion gene has been reported in 
males compared to females 55,59,60,62. Due to the gender composition with a male to female 
ratio of 5:1 and the recorded high WBC count ( >100 x 109/l)  in 18 of the 38 patients in our 
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study group, we still argue that this was a suitable group for analysis of STIL-TAL1 fusion, 
hence valid use of this unique material and of research money.  
4.2 STUDY II-IV  
p53 expression was found to be aberrant in patients who relapsed after HSCT in all three 
studies but at different time points during treatment (Table 1).  
Table 1: Characteristics and results of study II, III and IV 
Study Leukemic 
subtype 
Number of 
patients 
Time point 
for result 
Results* 
 
II 
 
MDS, JMML 
and CML 
 
33 
 
Diagnosis 
 
Increased p53 expression predicted relapse, OR 
1.19 (95% CI: 1.02-1.40, p = .028) 
 
III 
 
AML 
 
34 
 
3-6 months 
post HSCT 
 
Significant difference in p53 expression between 
relapse group and non-relapse group, with  
higher expression in relapse group (p = .010) 
 
IV 
 
ALL 
 
46 
 
0-3 months 
post HSCT 
 
Strong p53 expression predicted relapse, OR 
2.63 (95% CI: 1.08-6.40, p = .033) 
*Logistic regression study II and IV. Independent t-test in study III. 
 
Saft et al, showed that analysis of p53 expression by IHC is a clinical useful tool for 
prognosis in patients diagnosed with MDS. Strong expression of p53 in ≥1% of cells, 
measured by IHC and laser micro dissection was associated with transformation to AML and, 
to poor overall survival in a group of MDS otherwise classified as low- or intermediated risk 
patients 128. Interestingly, in the same study they also found an underlying mutation in TP53 
in the cells that strongly overexpressed the protein. In our studies of myeloid malignancies 
(study II and III) we calculated and suggested cut off levels of approximately 20% (19% and 
21.3% respectively) of p53 positive cells in children diagnosed with MDS, JMML, CML and 
AML. In contrast to the study by Saft et al, we considered all p53 positive cells which could 
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be an explanation to the large difference in cut off levels. However, in our study IV where we 
analyzed strong expression in ALLs, we suggest that > 2% of cells with strong expression of 
p53 indicated increased risk of relapse which is more in agreement with the results of Saft et 
al, indicating that intense p53 expression in only a few cells can be a signal of disease 
progression.  
Furthermore, at time of diagnosis p53 expression was increased in patients with 
hematological malignancies as compared to non-malignant controls in all three leukemic 
groups studied, indicating an involvement in leukemia (Figure 1). The control group had a 
lower expression of p53 protein at diagnosis than the leukemic patients, even when children 
with pre-malignant disorders were included (see study II and III). The decision to exclude the 
pre-malignant disorders from the control group was made solely with the intention to refine 
our material and did not have any substantial impact on our results.  
 
Figure 1: p53 expression at diagnosis in control group (n=42) compared to leukemic patients.  
MJC = MDS, JMML, CML group, NR = non-relapse group, R = relapse group, + = strong expression.  
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An interesting observation at time of diagnosis is that in the myeloid malignancies (MDS, 
JMML, CML and AML) the group of patients who relapsed after HSCT have a higher 
expression of p53 at diagnosis compared to the non-relapse patients. However, at time of 
diagnosis for ALL patients, the non-relapse patients had a higher expression of both total and 
strong p53 than the relapse group. This indicates that the underlying mechanism for the 
increased protein expression differs between the malignant cells depending on their lineage. 
 In the group with MDS, JMML and CML patients, the significant result in our study II was 
seen at diagnosis which is in agreement with the findings in the paper by Jädersten et al, 
where TP53 mutations were shown to be an early event in MDS patients 129. It could be that 
the increased expression of p53 in the myeloid malignancies indicates a more aggressive 
disease as seen in MDS patients in previous studies 128,129. In contrast to MDS, TP53 
mutations are rare at diagnosis of ALL and the increased percentage of cells expressing p53 
seen in the non-relapse group could be a normal response to DNA damage or cellular stress 
as an attempt to prevent the tumor to proliferate. Yet, in some ALL patients the altered p53 
expression may still represent a more aggressive clone that resists therapy and still remains 
after HSCT and thus may contribute to relapse. It would be interesting to study the 
underlying mechanisms of the altered p53 expression in the different leukemic subtypes to 
better understand the differences seen in our studies.  
MRD analysis is important for accurate risk stratification and there are defined time points for 
these analysis in treatment protocols. These set times are sometimes delayed due to poor 
cellular bone marrow regeneration causing inadequate samples for laboratory analysis, hence 
bone marrow aspirations are postponed or repeated at a later time. It has been shown that 
delayed bone marrow aspiration for MRD analysis has resulted in lower levels of MRD 
hence this could affect risk stratification and in turn survival 130. Another important factor for 
accurate MRD analysis are the numbers of markers that can be used in the analysis. One 
marker is associated with higher rate of negative results than two or more markers, as DNA 
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yield may be small in these patient samples the chances of successfully identify the same 
marker in two consecutive samples are limited. 130. We have shown in our studies, that p53 
expression is altered in pediatric ALL and AML patients after HSCT. If these alterations are 
due to an underlying genetic mutation in TP53 in the leukemic clone, TP53 analysis may 
have potential as a MRD marker in pediatric patients with leukemia after HSCT.  
Although leukemia is the most common cancer in childhood it is still a rare disease. And as 
knowledge increases more leukemic subtypes arise, creating the possibility to more 
individualized treatment. It also encourages international research collaborations to attain 
homogenic study populations large enough to preform statistical analysis that one can draw 
valid conclusions from. One limitation in this thesis, especially for study II- IV, was the small 
sample sizes. To validate the potential of p53 analysis as a marker for relapse, one would like 
to take into account confounding factors such as; related or unrelated donor, donor source, 
donor age, conditioning, DLI and other factors that are known in influence outcome. This 
was not possible in our material due to limitations in the statistical methods when including 
too few participants.  
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5 CONCLUSION AND FUTURE PERSPECTIVES  
 
Molecular markers are important tools to improve treatment and to achieve increased survival 
in children with leukemia. They can be used for risk stratification, monitoring disease 
progression and remission status, as target for development of new drugs, and for our 
essential need for an increased understanding of development of pediatric leukemia.  
This thesis resulted in the following conclusions: 
Study I: We suggest that STIL-TAL1 fusion gene most probably occurs as a post-natal genetic 
event in T-cell leukemia. 
Study II-IV: Aberrant expression of p53 protein seems to have potential as a predictive 
marker for relapse in different subtypes of pediatric leukemia. We conclude that increased 
p53 expression at diagnosis of MDS, JMML and CML may have potential as a marker to 
identify patients with inferior outcome after HSCT. For children with ALL and AML, 
monitoring of p53 expression after HSCT could be useful as a predictive marker for relapse 
in combination with conventional MRD and chimerism analysis. 
Cancer therapies are severe and potential life-threatening treatments and it is vital that each 
patient´s treatment is in proportion to the severity and complexity of their individual disease. 
The importance of biological makers as an instrument to optimize risk stratification and as 
targets for new drug development in leukemia is repeatedly called for in the scientific 
literature.  
Future studies would be necessary to validate the findings of our protein studies. They would 
need to include more patients; hence international collaborations should be encouraged. It 
would be interesting to explore the underlying mechanisms of the altered protein expression. 
One method that we have considered is single cell analysis, which makes is possible to pick 
out, and perform genetic analysis in the specific cells one would be interested in to investigate 
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further. This would be especially intriguing considering the results in our study IV, where an 
intense expression of p53 protein in approximately 2% of the cells was predictive of relapse 
after HSCT. I would also suggest that expression of the p53 regulating protein MDM2 and 
perhaps other p53 associated proteins were analyzed to indicate other possible underlying 
factors that can be the reason for the accumulation of p53 protein in the nucleus and that 
may affect the p53 pathway in the cell, as p53 is part of a complex cellular network 131.    
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Leukemi drabbar ca 70 barn varje år i Sverige och utgör en tredjedel av all cancer hos barn. 
Den vanligaste formen av barnleukemi kallas akut lymfatisk leukemi (ALL), följt av akut 
myeloisk leukemi (AML) och tillsammans utgör dom ca 95% av barnleukemier (80% och 
15% respektive). De mindre vanliga leukemidiagnoserna är kronisk myeloisk leukemi 
(KML), juvenil myelomonocytleukemi (JMML) och myelodysplastiskt syndrom (MDS).  
Sedan 1960-talet har barn som blir botade från leukemi ökat från ca 10% till idag då ca 
90% av ALL patienter och nästa 80% av AML patienter överlever sin diagnos.  För övriga 
diagnoser ligger överlevanden på ca 50-80%. Den positiva utvecklingen beror på de senaste 
decenniernas förbättrade behandling med mer specifika mediciner, bättre omvårdnad och 
mer kunskap om biologiska markörer som kan bidra till risklassificering av patienter, vara 
mål för medicinutveckling och som kan användas för att kunna följa eventuellt kvarvarande 
leukemiceller i barnet under och efter behandling.  
Trots att de flesta barn med leukemi numer blir botade så finns det fortfarande en liten 
grupp som utvecklar en mer aggressiv sjukdom som kräver tuffare behandling och som då 
kan behöva genomgå en hematopoietisk stamcellstransplantation. Det gäller framför allt 
ALL och AML patienter som svarat dåligt på standardbehandling, de som fått återfall eller 
om de blivit diagnosticerade med specifika genetiska avvikelser. Alla barn med MDS och 
JMML får också genomgå stamcellstransplantation. 
Vissa genetiska avvikelser är vanligt förekommande vid leukemidiagnos och intressant nog 
så har några av dessa kunna spårats tillbaka till barnets födelse genom studier av så kallade 
PKU-blodprov (nyföddhetsblodprov) där man kunnat påvisa att den genetiska avvikelsen 
fanns i några av barnets celler innan det insjuknade i leukemi.  
Denna avhandling har fokuserat på biologiska markörer i barnleukemi då vi har tittat om vi 
kunde påvisa en genetisk avvikelse, som är vanlig hos barn som drabbas av en ovanlig form 
av ALL, i deras PKU-korts samt studerat om uttryck av specifika proteiner kan förutse ett 
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återfall hos barn som genomgått HSCT.  
 
Studie I 
STIL-TAL1 är en fusionsgen som förkommer hos ca 11-27% av alla barn som diagnosticeras 
med T-cells ALL. T-cells ALL utgör ca 15% av alla lymfatiska leukemier och är vanligare 
bland lite äldre barn runt 10 år. Vi undersökte förekomsten av denna fusionsgen i PKU-
blodprov från 38 patienter som fått diagnosen T-cells ALL under barndomen. Genom att 
extrahera DNA från de sparade korten kunde vi med hjälp av specifika primersekvenser 
som fäster just på STIL-TAL1 fusionsgenen kopierar upp den i en polymeraskedjereaktion 
och därmed undersöka om den gick att hitta i något av barnens PKU-kort. Vi kunde inte 
påvisa att något av barnen skulle vara fött med denna fusionsgen och vår slutsats är att 
denna genetiska avvikelse sker i ett senare stadie av leukemiutvecklingen.  
 
Studie II-IV 
Tumörsuppressorgenen TP53, är också är känd som “guardian of the genome” då den har 
en nyckelroll i celldelning. TP53 kodar ett protein som ser till att skadat DNA inte förs 
vidare till en ny cell, genom att signalera lagning av DNA eller genom att initiera cellens 
självmordsprogram, kallat apoptos. TP53 är den mest muterade genen i cancer. Ca 50% av 
solida tumörer har mutationer i denna gen och den har även hittats i ca 10-20% av 
hematologiska tumörer hos vuxna, vanligtvis förknippat med mer aggressiv sjukdom. 
I ALL hos barn förekommer mutationer i TP53 oftare hos de barn som får återfall i sin 
sjukdom efter initial behandling. Därför ville vi undersöka om ett förändrat uttryck av p53 
proteinet kan förutse ett kommande återfall hos barn med mer svårbehandlad leukemi som 
får genomgå HSCT. p53 proteinet analyserades med immunhistokemi, en metod där 
specifika proteiner färgas och blir synliga i ett mikroskop. Vi undersökte uttrycket av p53 
vid i de olika subgrupperna av leukemi vid diagnos, innan HSCT och vid efterföljande 
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rutinkontroller vid ca 0-3, 3-6 och 6-12 månader efter HSCT. I gruppen med 33 patienter 
med de ovanligare myeloida diagnoserna MDS, JMML och KML så var ett ökat uttryck av 
p53 vid diagnos predicerande för återfall efter HSCT. I gruppen med 34 AML patienter såg 
vi att de barn som fick återfall hade ett högre uttryck av p53 vid 3-6 månader efter HSCT 
än de som inte fick återfall. Slutligen analyserade vi 46 ALL patienter och då var det de 
som hade ett strakt uttryck av p53 vid 0-3 månader efter HSCT, dvs de som hade celler som 
var starkt färgade när man tittade i mikroskopet, som hade högre risk att få återfall än de 
som hade ett svagare uttryck. Vi konkluderar att p53 uttryck, analyserat med 
immunhistokemi som är en vanlig och tillgänglig metod i kliniken, har potential som en 
prognosmarkör hos barn med leukemi och att detta borde studeras ytterligare i en större 
studie med fler patienter.  
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